The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Glioblastoma multiforme: The terminator
Open accessAbstract
Glioblastoma multiforme is the most aggressive of the gliomas, a collection of tumors arising from glia or their precursors within the central nervous system. Clinically, gliomas are divided into four grades; unfortunately, the most aggressive of these, grade 4 or glioblastoma multiforme (GBM), is also the most common in humans. Because most patients with GBMs die of their disease in less than a year and essentially none has long-term survival, these tumors have drawn significant attention; however, they have evaded increasingly cleaver and intricate attempts at therapy over the last half-century. The paper by Gromeier et al. (1) in this issue of PNAS is the newest chapter in this saga, describing a hybrid virus that infects and kills clonal human glioma cell lines, in culture and implanted in athymic mice, without affecting nonneoplastic cells within the brain. For those viewing this battle from a distance, the continued unsuccessful attempts at novel therapies for this disease may be difficult to understand. However, for those treating these patients, and certainly for the patients themselves, the importance and urgency of each attempt is clear.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Culver, K. W., Ram, Z., Wallbridge, S., Ishii, H., Oldfield, E. H., & Blaese, R. M. (1992) · Science · doi:10.1126/science.1317968 · Cited by 1,509
Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53
Livingstone, L. R., White, A., Sprouse, J., Livanos, E., Jacks, T., & Tlsty, T. D. (1992) · Cell · doi:10.1016/0092-8674(92)90243-6 · Cited by 1,332
Reversible Tumorigenesis by MYC in Hematopoietic Lineages
Felsher, D. W., & Bishop, J. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80367-6 · Cited by 881
Essential role for oncogenic Ras in tumour maintenance
Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., Shen, Q., O'Hagan, R., Pantginis, J., Zhou, H., et al. (1999) · Nature · doi:10.1038/22788 · Cited by 875
Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas
Mineta, T., Rabkin, S. D., Yazaki, T., Hunter, W. D., & Martuza, R. L. (1995) · Nature Medicine · doi:10.1038/nm0995-938 · Cited by 822
Reversible Activation of c-Myc in Skin
Pelengaris, S., Littlewood, T., Khan, M., Elia, G., & Evan, G. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80350-0 · Cited by 468
Intergeneric poliovirus recombinants for the treatment of malignant glioma
Gromeier, M., Lachmann, S., Rosenfeld, M. R., Gutin, P. H., & Wimmer, E. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.12.6803 · Cited by 363
The Treatment of Glioblastoma Multiforme of the Brain
Jelsma, R., & Bucy, P. C. (1967) · Journal of Neurosurgery · doi:10.3171/jns.1967.27.5.0388 · Cited by 233
Ishii, N., Tada, M., Hamou, M. F., Janzer, R. C., Meagher‐Villemure, K., Wiestler, O., de Tribolet, N., & Meir, E. G. V. (1999) · Oncogene · doi:10.1038/sj.onc.1203241 · Cited by 87
Successful Treatment of a Malignant Rat Glioma with Cytotoxic T Lymphocytes
Holladay, F. P., Heitz, T., Chen, Y.-L., Chiga, M., & Wood, G. W. (1992) · Neurosurgery · doi:10.1227/00006123-199209000-00015 · Cited by 47
Cited by
Hanif, F., Muzaffar, K., Perveen, K., Malhi, S. M., & Sımjee, S. U. (2017) · PubMed · doi:10.22034/apjcp.2017.18.1.3 · Cited by 1,231
Vescovi, A. L., Galli, R., & Reynolds, B. A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1889 · Cited by 990
Matrix metalloproteinases in the brain and blood–brain barrier: Versatile breakers and makers
Rempe, R. G., Hartz, A. M., & Bauer, B. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16655551 · Cited by 721
Brennan, C., Momota, H., Hambardzumyan, D., Ozawa, T., Tandon, A., Pedraza, A., & Holland, E. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007752 · Cited by 534
Self-citationThe hypoxic response of tumors is dependent on their microenvironment
Blouw, B., Song, H., Tihan, T., Bosze, J., Ferrara, N., Gerber, H.-P., Johnson, R. S., & Bergers, G. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00194-6 · Cited by 408
Rahaman, S. O., Harbor, P. C., Chernova, O., Barnett, G. H., Vogelbaum, M. A., & Haque, S. J. (2002) · Oncogene · doi:10.1038/sj.onc.1206047 · Cited by 377
Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion
Grobben, B., De Deyn, P., & Slegers, H. (2002) · Cell and Tissue Research · doi:10.1007/s00441-002-0651-7 · Cited by 365
Development of a novel mouse glioma model using lentiviral vectors
Marumoto, T., Tashiro, A., Friedmann-Morvinski, D., Scadeng, M., Soda, Y., Gage, F. H., & Verma, I. M. (2009) · Nature Medicine · doi:10.1038/nm.1863 · Cited by 353
Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma
DeCordova, S., Shastri, A., Tsolaki, A. G., Yasmin, H., Klein, L., Singh, S. K., & Kishore, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01402 · Cited by 346
Transplanted glioma cells migrate and proliferate on host brain vasculature: A dynamic analysis
Farin, A., Suzuki, S. O., Weiker, M., Goldman, J. E., Bruce, J. N., & Canoll, P. (2006) · Glia · doi:10.1002/glia.20334 · Cited by 343
The molecular profile of microglia under the influence of glioma
Li, W., & Graeber, M. B. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos116 · Cited by 340
Automated Network Analysis Identifies Core Pathways in Glioblastoma
Cerami, E., Demir, E., Schultz, N., Taylor, B. S., & Sander, C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008918 · Cited by 333
Microglia Stimulate the Invasiveness of Glioma Cells by Increasing the Activity of Metalloprotease-2
Markovic, D. S., Glass, R., Synowitz, M., Rooijen, N. V., & Kettenmann, H. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000178445.33972.a9 · Cited by 317
Spatiotemporal Evolution of the Primary Glioblastoma Genome
Kim, J., Lee, I.-H., Cho, H. J., Park, C.-K., Jung, Y.-S., Kim, Y., Nam, S. H., Kim, B. S., Johnson, M. D., Kong, D.-S., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.07.013 · Cited by 314
Inhibition of tumor angiogenesis by cannabinoids
Blázquez, C., Casanova, M. L., Planas, A., Gómez del Pulgar, T., Villanueva, C., Fernández‐Aceñero, M. J., Aragonés, J., Huffman, J. W., Jorcano, J. L., & Guzmán, M. (2003) · The FASEB Journal · doi:10.1096/fj.02-0795fje · Cited by 292
WNT signaling in glioblastoma and therapeutic opportunities
Lee, Y., Lee, J.-K., Ahn, S. H., Lee, J., & Nam, D.-H. (2016) · Laboratory Investigation · doi:10.1038/labinvest.2015.140 · Cited by 273
Cancer Stem Cell Hierarchy in Glioblastoma Multiforme
Bradshaw, A., Wickremsekera, A., Tan, S. T., Peng, L., Davis, P. F., & Itinteang, T. (2016) · Frontiers in Surgery · doi:10.3389/fsurg.2016.00021 · Cited by 258
Elshafeey, N., Kotrotsou, A., Hassan, A., Elshafei, N., Hassan, I., Ahmed, S., Abrol, S., Agarwal, A., El Salek, K., Bergamaschi, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11007-0 · Cited by 147
Huang, R., Harmsen, S., Samii, J. M., Karabeber, H., Pitter, K. L., Holland, E. C., & Kircher, M. F. (2016) · Theranostics · doi:10.7150/thno.13842 · Cited by 111
Self-citationLost in disruption: Role of proteases in glioma invasion and progression
Mentlein, R., Hattermann, K., & Held-Feindt, J. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.12.001 · Cited by 85
Therapeutic Prospects of mRNA-Based Gene Therapy for Glioblastoma
Tang, X., Zhang, S., Fu, R., Zhang, L., Huang, K., Peng, H., Dai, L., & Chen, Q. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01208 · Cited by 69
Revisiting the role of p53 in primary and secondary glioblastomas.
(2006) · PubMed · Cited by 51
Metadata
- Authors
- Holland, E. C.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2000-06-06
- Volume
- 97
- Issue
- 12
- Pages
- 6242-6244
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1993034243
- Cited by
- 762
- References
- 11
- FWCI
- 6.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.